Trump Administration Eyes New Drug Pricing Probe

The Trump administration is organizing a probe into the drug pricing tactics of U.S. trading partners, potentially leading to new tariffs. This investigation, under Section 301 of the Trade Act, focuses on whether trading partners are underpaying for drugs. This could lead to significant changes in drug pricing strategies.

The Trump administration is taking steps toward launching an investigation into drug pricing practices among U.S. trading partners, which could lead to the imposition of new tariffs. According to a report from the Financial Times, this investigation will be conducted under Section 301 of the Trade Act of 1974.

Sources suggest that the probe will examine if trading partners are underpaying for U.S. pharmaceuticals, in light of the high prices borne by American patients. The report, however, remains unverified by Reuters, and no immediate comment was provided by the White House.

The potential move reflects ongoing pressure from President Trump, who has threatened a 100% tariff on imported branded pharmaceutical products unless manufacturing facilities are established in the U.S., a step yet to be actualized as Trump continues his push for lower drug prices.